Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study is a research paper published in ESMO Open (2021). On theSindex it has a DataRank of 0.396. It has been cited 13 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.396
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →American Cancer Society
Grant: 133835-CSDG-19-153-01-PCSM
National Institutes of Health
Grant: P30 CA016672
National Institutes of Health
Grant: R01CA242845
American Society of Clinical Oncology
Grant: 12895
Heron Therapeutics
Grant: KEYNOTE-695
Jazz Pharmaceuticals
Grant: unidentified
unidentified
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
National Institutes of Health
Grant: 5R01CA242845-04
Blocking tumor progression in therapy-responsive RET aberration-associated cancer
The University of Texas MD Anderson Cancer Center
American Cancer Society
National Institutes of Health
ASCO
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals